Alzheimer's Disease Clinical Trial
Official title:
Alzheimer's Caregiver Ratings of Communication & Coping Behavior
The point of this research is to improve the communicative relationship between the caregiver and care receiver. It is input from the caregiver on these communicative behaviors that will inform the process of understanding how to reduce the caregiver burden that comes from this communicative relationship.
This research study is developing a new checklist to measure communicative coping behaviors
of persons with Alzheimer's Disease in the home environment. The Communicative Coping
Behavior Checklist (CCBC) is an observation checklist to be completed by the caregiver or
knowledgeable informant. The current version includes 23 behaviors to be rated for frequency
and effectiveness. The behaviors that will be observed cover management of memory loss
within three broad categories: humor, explanations, and general coping behaviors.
Two kinds of couples will participate in this study. One includes a person with Alzheimer's
Disease and their caregiver. The second includes a cognitively intact participant and study
partner, both over the age of 60, to serve as controls.
Study Visit 1 (3 hours long) During the first visit, the person with Alzheimer's
Disease/control participant can expect to be asked questions about their memory, thinking
and concentration, demographics, quality of life, and mood. The caregiver/study partner will
be asked about their quality of life, mood, and daily activities.
At the end of the visit the caregiver/study partner will be given a copy of the CCBC and
asked to take it home. S/he will be instructed to rate the person with Alzheimer's Disease/
control participant's communicative coping behavior over the course of the next two weeks.
At the end of that time, a research assistant will call the caregiver/study partner and
administer the CCBC over the telephone.
Study Visit 2 (3 hours long) The second visit will occur in the clinic approximately 12
months from the date of the first visit. As with the first study visit, again both the
person with Alzheimer's Disease/control participant and the caregiver/study partner will
answer questions about their memory, quality of life, mood, and daily activities. Once
again, the caregiver/study partner will be given a copy of the CCBC and asked to take it
home and complete.
Both visits will take about three hours for the caregiver/study partner and about two hours
for the person with dementia or control subject.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
| Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
| Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
| Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
| Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
| Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
| Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
| Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
| Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
| Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
| Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
| Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
| Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
| Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
| Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
| Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
| Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
| Not yet recruiting |
NCT01940952 -
Zydena on Cognitive Function of Alzheimer's Disease Patients
|
Phase 3 |